Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

Table 3 Secondary effectiveness outcomes

	ARNI (N = 87)	Standard treatment (N = 100)	p-value
Clinical signs and symptoms of HF (%)
Dyspnea	6 (6.9)	22 (22.0)	0.004
Orthopnea*	5 (5.8)	16 (16.0)	0.036
Fatigue*	2 (2.3)	14 (14.0)	0.004
Edema	40 (46.0)	58 (58.0)	0.101
Changes of HF-specific parameters**
NT-proBNP (pg/mL)	− 466 (2011)	− 81 (2341)	0.170
LVEF (%)	+ 13.0 (16.0)	+ 12.0 (16.8)	0.389

LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro B-type natriuretic peptide,
^*Fisher Exact test
^**Reported as median (interquartile range)
^***Changes of NT-proBNP was reported in 57 and 59 patients in ARNI group and standard treatment group, respectively
−Changes of LVEF was reported in 51 and 60 patients in ARNI group and standard treatment group, respectively

ISSN: 1471-2261